Recent News
Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma (BIMES)
Primary Outcome Measures To evaluate the efficacy of the treatment [ Time Frame: From the date of randomization to the date of last follow up, assessed up to 24 months ] To determine the…
Radiation Does Not Improve Survival in Pleural Mesothelioma Patients
A study at the Duke University Medical Center has found that radiation does not extend survival in pleural mesothelioma patients. A dual registry analysis was performed to determine the effectiveness…
ONCOFID-P Was Given Orphan Drug Status to Treat Pleural Mesothelioma
Pleural mesothelioma could soon have a new approved treatment option. The Food and Drug Administration just granted orphan drug status to ONCOFID-P for the treatment of the cancer. It is…
Researchers are Trying to Find New Treatments to Combine with Tumor Treating Fields
Tumor Treating Fields were approved for treating mesothelioma, and while they are effective, researchers want to make them more effective for the cancer. A researcher at the Humanitas University in…
CAR-T Cell Therapy and Keytruda is Showing Real Promise
Researchers at the Memorial Sloan Kettering Cancer Center are experimenting with a combination of CAR-T cell therapy and Keytruda, a PD-1 blocker for the treatment of pleural mesothelioma. This is…
A New Predictive Model Could Help Doctors Choose the Best Surgery for Mesothelioma Patients
Doctors could soon pick the best surgery for pleural mesothelioma patients because of a new predictive model created by Harvard researchers. There are different types of mesothelioma surgery: one involves…
Immunotherapy Treatment for Mesothelioma Could Become Safer and More Effective
Research could help create better and safer immunotherapy treatments for mesothelioma. Immunotherapy is a fast growing and exciting way to treat cancer because it uses the body’s own immune system…
UNITO-001-A Phase II Study Niraparib Plus Dostarlimab in HRR/PDL1 Positive MPM/NSCLC (UNITO-001)
This is a single arm, prospective, interventional, multicenter phase 2 study of the combination of niraparib and dostarlimab in patients with advanced non-small cell lung cancer (NSCLC) and/or malignant pleural mesothelioma (MPM), and positive for PD-L1 expression (TPS ≥ 1%) and germline or somatic mutations in the DNA homologous recombination repair (HRR) genes.
GPS Vaccine is Effective in Mesothelioma Patients When Paired with Opdivo
A new cancer vaccine was found to be effective in mesothelioma patients alongside Opdivo in a new study. It was studied in people whose cancer no longer responded to standard…
Stereotactic Body Radiation Therapy With Immunotherapy for the Treatment of Mesothelioma
This phase I trial studies the effect of stereotactic body radiation therapy and immunotherapy in treating patients with mesothelioma. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving stereotactic body radiation therapy and immunotherapy may improve the tumors response to the treatment and decrease side-effects.
